AACR 2021: Humanized CCR8 Mouse Model Provides A Translational Tool For Anti-Human CCR8 Antibody Drug Development

AACR 2021: Humanized CCR8 Mouse Model Provides A Translational Tool For Anti-Human CCR8 Antibody Drug Development

Author: Linlin Wang, Leila Kokabee, Yichao Chen, Xiaofei Zhou, Qingcong Lin, Zhaoxue (Luke) Yu

CCR8 is reported as an important chemokine receptor expressed on intra-tumoral Tregs and plays a critical role in CCR8+ Treg-mediated immunosuppression via inducing STAT3-dependent overexpression of FOXP3, CD39, IL-10, and granzyme B on Tregs with the interaction of CCL1 (CCR8 ligand). CCR8 becomes a promising target in the anticancer drug development. Generation of humanized CCR8 mouse models can greatly improve translation and accelerate CCR8-related drug development.

To evaluate the anti-tumor efficacy of human CCR8 blockade in tumor mouse models, Biocytogen has successfully generated a novel CCR8 humanized knock-in mouse strain to support anti-human CCR8 antibody drug development. In this mouse model, the full length of encoding sequences of the mouse CCR8 gene was replaced by the full length of encoding sequences of the human CCR8 (hCCR8) gene. CCR8 gene expression in wild-type and B-hCCR8 mice was tested by RT-PCR. Human CCR8 mRNA was detected in hCCR8 mice model but not in wild-type mice. Protein expression of human CCR8 in hCCR8 mice was evaluated by flow cytometer in a colon cancer cell line MC38 tumor-bearing mouse model. The human CCR8 protein was successfully detected in tumor-infiltrating Tregs in B-hCCR8 mice bearing MC38 tumors, but not in Treg cells from the spleen. An anti-tumor efficacy study showed significant tumor growth inhibition of hCCR8 antibodies in B-hCCR8 mice bearing MC38 tumors, suggesting that the B-hCCR8 mouse model is an effective tool for in vivo efficacy evaluation of therapeutic hCCR8 antibodies to support anti-human CCR8 antibody clinical development.

Share:

Please fill out the form below to request a download of this poster